SNOA Financials

Income Statement
MetricQ1 2027Q4 2026Q3 2026Q2 2026Q1 2026
Revenue
6.4M
+15.2%
5.6M
+27.9%
4.3M
-22.4%
5.6M
+39.6%
4.0M
Cost of Revenue
3.8M
+13.3%
3.4M
+25.2%
2.7M
-22.5%
3.5M
+36.6%
2.6M
Gross Profit
2.6M
+18.2%
2.2M
+32.2%
1.6M
-22.2%
2.1M
+44.8%
1.5M
Operating Expenses
2.6M
-25.0%
3.5M
+49.9%
2.3M
-5.3%
2.5M
-4.0%
2.6M
R&D
597.0K
+9.5%
545.0K
-2.2%
557.0K
-3.1%
575.0K
-3.2%
594.0K
SG&A
2.0M
+1.7%
2.0M
+12.2%
1.8M
-5.9%
1.9M
-4.2%
2.0M
Operating Income
-40000
+96.9%
-1309000
-93.1%
-678000
-101.2%
-337000
+69.2%
-1095000
EBITDA
-8000
+99.4%
-1276000
-98.1%
-644000
-114.0%
-301000
+71.6%
-1059000
Net Income
-330000
+43.2%
-581000
+29.1%
-819000
-53.4%
-534000
+57.0%
-1241000
EPS (Basic)
$-0.09
+72.7%
$-0.33
+31.2%
$-0.48
-50.0%
$-0.32
+57.9%
$-0.76
EPS (Diluted)
$-0.09
+72.7%
$-0.33
+31.2%
$-0.48
-50.0%
$-0.32
+57.9%
$-0.76
Shares (Diluted)
3.8M
+121.5%
1.7M
+1.3%
1.7M
+4.1%
1.6M
+0.3%
1.6M
Sonoma Pharmaceuticals (SNOA) โ€” Financials